• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Kenneth C. Anderson, MD

Publications

  • Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, Ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G.Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.Nat Med. 2014 Jun;20(6):599-606.
    24813251
  • Bianchi G, Richardson PG, Anderson KC.Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area.J Clin Oncol. 2014 Jun 2.
    24888801
  • Fulciniti M, Amodio N, Bandi RL, Munshi M, Yang G, Xu L, Hunter Z, Tassone P, Anderson KC, Treon SP, Munshi NC.MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.Blood. 2014 Apr 24;123(17):2673-81.
    24622324
  • Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.British Journal of Haematology. 2014 Apr 25.
    24761838
  • Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Sonneveld P P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Leukemia. 2014 Apr 15.
    24732597
  • Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.Blood. 2014 Mar 6;123(10):1461-9.
    24429336
  • Jones DR, Wu Z, Chauhan D, Anderson KC, Peng J.A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.Anal Chem. 2014 Apr 1;86(7):3667-75.
    24611431
  • Bianchi G, Anderson KC, Harris NL, Sohani AR.The heavy chain diseases: clinical and pathologic features.Oncology (Huntingt). 2014 Jan;28(1):45-53.
    24683718
  • Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC.Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.Blood. 2014 Mar 20;123(12):1826-32.
    24421329
  • Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, Tao J, Tai YT, Treon S, Pinkus G, Kuo WP, Hideshima T, Bouxsein M, Munshi N, Anderson K, Carrasco R.miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.Cancer Res. 2014 Mar 15;74(6):1801-13.
    24599134
  • Laubach JP, Tai YT, Richardson PG, Anderson KC.Daratumumab granted breakthrough drug status.Expert Opin Investig Drugs. 2014 Apr;23(4):445-52.
    24555809
  • Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC.Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity.Blood. 2014 Feb 25.
    24569262
  • Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T.IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.Int J Oncol. 2014 Apr;44(4):1171-6.
    24481412
  • Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC.Future agents and treatment directions in multiple myeloma.Expert Rev Hematol. 2014 Feb;7(1):127-41.
    24350987
  • Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC.A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.Blood. 2014 Jan 30;123(5):706-16.
    24319254
  • Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M.Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Blood. 2014 Jan 30;123(5):632-9.
    24335104
  • Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.Nat Commun. 2014;5:2997.
    24429703
  • Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K.Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.Cancer Lett. 2014 Feb 28;343(2):286-94.
    24120758
  • Richardson PG, Laubach J, Paba-Prada C, Anderson KC.IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities.Oncology (Huntingt). 2013 Aug;27(8):803-4, 806.
    24133830
  • Kang YJ, Zeng W, Song W, Reinhold B, Choi J, Brusic V, Yamashita T, Munshi A, Li C, Minvielle S, Anderson KC, Munshi N, Reinherz EL, Sasada T.Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.British Journal of Haematology. 2013 Nov;163(3):343-51.
    24032635
  • San-Miguel JF, Richardson PG, Günther A, Sezer O, Siegel D, Bladé J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC.Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.J Clin Oncol. 2013 Oct 10;31(29):3696-703.
    24019544
  • Wang Y, Lomakin A, Latypov RF, Laubach JP, Hideshima T, Richardson PG, Munshi NC, Anderson KC, Benedek GB.Phase transitions in human IgG solutions.J Chem Phys. 2013 Sep 28;139(12):121904.
    24089716
  • Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.Lancet Oncol. 2013 Oct;14(11):1129-40.
    24055414
  • Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP.A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.Blood. 2013 Aug 15;122(7):1222-32.
    23836557
  • Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.Blood. 2013 Aug 15;122(7):1243-55.
    23823317
  • Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D.Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.Clin Cancer Res. 2013 Jul 1;19(13):3640-8.
    23685836
  • Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N.Small molecule Multi-Targeted kinase inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple myeloma activity through inhibition of transcriptional CDKs.Leukemia. 2013 Jun 28.
    23807770
  • Munshi NC, Anderson KC.Minimal Residual Disease in Multiple Myeloma.J Clin Oncol. 2013 Jun 3.
    23733782
  • Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM.BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.J Clin Invest. 2013 Apr 1;123(4):1542-55.
    23454749
  • Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD, Anderson KC, Carrasco DR.TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.British Journal of Haematology. 2013 May 7.
    23647456
  • Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM.Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration.Biol Blood Marrow Transplant. 2013 Mar 29.
    23545332
  • Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth.Clin Cancer Res. 2013 Apr 15;19(8):2096-2106.
    23446999
  • O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Cancer Chemother Pharmacol. 2013 Apr 16.
    23589314
  • Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, .Salvage Second Hematopoietic Cell Transplantation in Myeloma.Biol Blood Marrow Transplant. 2013 May;19(5):760-6.
    23298856
  • Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC.Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.Leuk Res. 2013 Apr 9.
    23582718
  • Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi NC, Richardson PG, Lewensohn R, Anderson KC.In vitro and In vivo Antitumor Activity of a Novel Alkylating Agent Melphalan-flufenamide Against Multiple Myeloma Cells.Clin Cancer Res. 2013 Apr 12.
    23584492
  • Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC.Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.Blood. 2013 Apr 11;121(15):2975-87.
    23321256
  • Cea M, Cagnetta A, Patrone F, Nencioni A, Gobbi M, Anderson KC.Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.Autophagy. 2013 Mar;9(3):410-2.
    23221771
  • Munshi NC, Anderson KC.New Strategies in the Treatment of Multiple Myeloma.Clin Cancer Res. 2013 Mar 20.
    23515406
  • Hideshima T, Anderson KC.Histone deacetylase inhibitors in the treatment for multiple myeloma.Int J Hematol. 2013 Mar;97(3):324-32.
    23475757
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.Blood. 2013 Mar 14;121(11):1961-7.
    23243282
  • Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP.MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.Blood. 2013 Mar 14;121(11):2051-8.
    23321251
  • Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N.In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.Bone. 2013 Apr;53(2):487-96.
    23333523
  • Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Blood. 2013 Feb 21;121(8):1296-303.
    23287861
  • Voorhees PM, Laubach J, Anderson KC, Richardson PG.Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.Blood. 2013 Jan 31;121(5):858.
    23372151
  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG.Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.J Clin Oncol. 2013 Feb 1;31(4):448-55.
    23233713
  • Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P.Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.British Journal of Haematology. 2013 Feb;160(3):351-8.
    23240658
  • Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC.Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.J Immunol. 2013 Feb 1;190(3):1360-71.
    23293352
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R.Multiple myeloma, version 1.2013.J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7.
    23307977
  • Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P.Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence.Clin Cancer Res. 2012 Nov 15;18(22):6260-6270.
    23035210
  • Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP.Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.British Journal of Haematology. 2012 Nov 15.
    23150997
  • Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC.Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.Blood. 2012 Nov 8;120(19):3958-67.
    22983447
  • Potash J, Anderson KC.Gauging progress in a decades-old fight.Clin Cancer Res. 2012 Nov 1;18(21):5833.
    22977189
  • Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.Blood. 2012 Oct 25;120(17):3519-29.
    22955917
  • Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA.Pre-diagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.Blood. 2012 Oct 16.
    23074271
  • Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A.GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo.Cancer Res. 2012 Oct 15;72(20):5374-5385.
    22942257
  • Tai YT, Anderson KC.Bruton's tyrosine kinase: oncotarget in myeloma.Oncotarget. 2012 Sep;3(9):913-4.
    22989914
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA.Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013.J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-1219.
    23054875
  • Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS.Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.British Journal of Haematology. 2012 Nov;159(3):340-51.
    22970818
  • Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC.Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.Blood. 2012 Sep 27.
    23018640
  • Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T, Anderson KC.New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors.Curr Pharm Des. 2012 Sep 26.
    23016853
  • van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG.How I treat plasma cell leukemia.Blood. 2012 Sep 20;120(12):2376-89.
    22837533
  • Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC.A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Cancer Cell. 2012 Sep 11;22(3):345-58.
    22975377
  • van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Cancer Management and Research. 2012;4:253-68.
    22956884
  • Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.Clin Cancer Res. 2012 Sep 1;18(17):4669-81.
    22806876
  • Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC.Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.Clin Cancer Res. 2012 Sep 1;18(17):4850-60.
    22753586
  • Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.Blood. 2012 Aug 30;120(9):1877-87.
    22689860
  • Wang Y, Lomakin A, Hideshima T, Laubach JP, Ogun O, Richardson PG, Munshi NC, Anderson KC, Benedek GB.Pathological crystallization of human immunoglobulins.Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13359-61.
    22847421
  • Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC.Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.British Journal of Haematology. 2012 Aug;158(4):472-80.
    22640031
  • Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC.Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma.Blood. 2012 Jul 20.
    22821765
  • Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS.Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.Mol Cancer Ther. 2012 Jul;11(7):1432-42.
    22474168
  • Saboo SS, Fennessy F, Benajiba L, Laubach J, Anderson KC, Richardson PG.Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.J Clin Oncol. 2012 Jul 10;30(20):e175-9.
    22689802
  • Mahindra A, Anderson KC.Role of Interleukin 16 in Multiple Myeloma Pathogenesis: * A Potential Novel Therapeutic Target?.Journal of the National Cancer Institute. 2012 Jun 28.
    22745468
  • Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D.Lenalidomide enhances anti-myeloma cellular immunity.Cancer Immunol Immunother. 2012 Jun 24.
    22733396
  • Hideshima T, Anderson KC.Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.Semin Hematol. 2012 Jul;49(3):223-7.
    22726545
  • Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC.A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.Blood. 2011 Mar 31.
    21454451
  • Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.Tanespimycin as antitumor therapy.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):17-22.
    21454186
  • Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen H, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, Lonial S.International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation.Blood. 2011 Mar 29.
    21447828
  • Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig SJ, Vallet S, Pozzi S, Patel K, Unitt CL, Squires MS, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje NS.Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide.Clin Cancer Res. 2011 Mar 23.
    21430070
  • Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR.Initial genome sequencing and analysis of multiple myeloma.Nature. 2011 Mar 24;471(7339):467-72.
    21430775
  • Laubach J, Richardson PG, Anderson K.Hematology: Setting the standard for newly diagnosed multiple myeloma.Nat Rev Clin Oncol. 2011 Mar 22.
    21423257
  • Anderson KC.Oncogenomics to target myeloma in the bone marrow microenvironment.Clin Cancer Res. 2011 Mar 15;17(6):1225-33.
    21411438
  • Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.Lancet Oncol. 2011 Mar;12(3):263-72.
    21345726
  • Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P.A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.Proteomics. 2011 Feb 14.
    21365752
  • Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Expert Rev Hematol. 2011 Feb;4(1):51-60.
    21322778
  • Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.Blood. 2011 Feb 14.
    21321360
  • Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI.Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.Clin Chim Acta. 2011 Mar 18;412(7-8):562-8.
    21144845
  • Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J.Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.Blood. 2011 Feb 3.
    21292775
  • Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H.Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.Blood. 2011 Feb 3.
    21292777
  • Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S.Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.Blood. 2011 Feb 3.
    21292778
  • Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP.Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.J Biomed Opt.;16(1):011006.
    21280893
  • Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.British Journal of Haematology. 2011 Feb;152(4):367-79. Review.
    21219297
  • McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.British Journal of Haematology. 2011 Feb;152(4):420-32.
    21223249
  • Anderson KC, Carrasco RD.Pathogenesis of myeloma.Annu Rev Pathol. 2011 Feb 28;6:249-74.
    21261519
  • de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW.Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.J Immunol. 2011 Feb 1;186(3):1840-8.
    21187443
  • Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.Blood. 2011 Jan 13;117(2):393-402.
    21030562
  • Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC.PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.British Journal of Haematology. 2011 Jan;152(2):155-63.
    21114484
  • Dimopoulos MA, San-Miguel JF, Anderson KC.Emerging Therapies for the Treatment of Relapsed or Refractory Multiple Myeloma.Eur J Haematol. 2011 Jan;86(1):1-15.
    20942854
  • Mahindra A, Hideshima T, Anderson KC.Multiple myeloma: biology of the disease.Blood Rev. 2010 Nov;24 Suppl 1:S5-11.
    21126636
  • Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC.A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma.Blood. 2010 Dec 2;116(23):4906-15.
    20805366
  • Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Rajkumar SV, Durie BG, San Miguel J.Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group.J Clin Oncol. 2010 Nov 20;28(33):4976-84. Review.
    20956629
  • Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.Blood. 2010 Oct 28;116(17):3227-37.
    20651070
  • Gatt ME, Zhao JJ, Ebert MS, Zhang Y, Chu Z, Mani M, Gazit R, Carrasco DE, Dutta-Simmons J, Adamia S, Minvielle S, Tai YT, Munshi NC, Avet-Loiseau H, Anderson KC, Carrasco DR.MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.Blood. 2010 Oct 20.
    20962322
  • Rourke M, Anderson KC, Ghobrial IM.Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.Leuk Lymphoma. 2010 Oct;51(10):1779-92.
    20795787
  • Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.Am J Hematol. 2010 Sep;85(9):670-4.
    20652865
  • Ikeda H, Hideshima T, Fulciniti M, Perrone G, Mimura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cirstea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC.PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.Blood. 2010 Sep 2;116(9):1460-8.
    20505158
  • Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG.Kidney disease associated with plasma cell dyscrasias.Blood. 2010 Sep 2;116(9):1397-404. Review.
    20462963
  • Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ.JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.J Pharm Pharmacol. 2010 Jan;62(1):145-51.
    20723011
  • Potash J, Anderson KC.What can CCR do for you?.Clin Cancer Res. 2010 Aug 15;16(16):4069-70.
    20682715
  • Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.British Journal of Haematology. 2010 Aug;150(4):428-37.
    20618338
  • Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC.Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.British Journal of Haematology. 2010 Aug;150(4):438-45.
    20618337
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
    20385792
  • Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA.Monoclonal gammopathy of undetermined significance: a consensus statement.British Journal of Haematology. 2010 Jul;150(1):28-38.
    20507313
  • Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC.Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.Blood. 2010 Jul 1;115(26):5385-92.
    20395418
  • Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC.A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.Blood. 2010 Jun 24;115(25):5202-13.
    20382844
  • Laubach JP, Richardson PG, Anderson KC.The evolution and impact of therapy in multiple myeloma.Med Oncol. 2010 Jun;27 Suppl 1:S1-6. Review.
    20169425
  • Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J.Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.Clin Cancer Res. 2010 Jun 15;16(12):3260-9.
    20530693
  • Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, .Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.Leukemia. 2010 Jun;24(6):1121-7. Review.
    20410922
  • Podar K, Anderson KC.A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.Cell Cycle. 2010 May;9(9):1722-8. Review.
    20404562
  • Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM.Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.Blood. 2010 May 20;115(20):4051-60.
    20110419
  • Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC.A proto-oncogene Bcl-6 is upregulated in the bone marrow microenvironment in multiple myeloma cells.Blood. 2010 May 6;115(18):3772-5.
    20228272
  • Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC.Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.British Journal of Haematology. 2010 May;149(4):550-9.
    20331453
  • Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.British Journal of Haematology. 2010 May;149(4):537-49.
    20331454
  • Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD, Annunziata CM, Munshi NC.The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.Blood. 2010 Apr 8;115(14):2827-34.
    19965618
  • Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.Mol Cancer Ther. 2010 Apr;9(4):963-75.
    20371718
  • McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS.Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.Nat Med. 2010 Apr;16(4):483-9.
    20228816
  • Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N.Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5124-9.
    20194748
  • Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.J Clin Oncol. 2010 Mar 10;28(8):1422-8.
    20142586
  • Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.J Clin Oncol. 2010 Mar 10;28(8):1408-14.
    20142598
  • Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K.Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12.
    20141673
  • Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.Clin Cancer Res. 2010 Feb 1;16(3):1033-41.
    20103671
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4.
    20118399
  • Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Blood. 2010 Jan 28;115(4):834-45.
    19965674
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
    20018760
  • Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia..
  • Anderson KC.From the guest editor: the evolving treatment paradigm in multiple myeloma.Cancer J.;15(6):456.
    20010163
  • Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, Tassone P, Anderson KC, Munshi NC.A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
    19934301
  • Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.Clin Cancer Res. 2009 Dec 1;15(23):7153-60.
    19934289
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.J Clin Oncol. 2009 Dec 1;27(34):5713-9.
    19786667
  • Mitsiades CS, Anderson KC.Epigenetic modulation in hematologic malignancies: challenges and progress.J Natl Compr Canc Netw. 2009 Nov;7 Suppl 8:S1-12; quiz S14-6. Review.
    19930971
  • Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS.In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.British Journal of Haematology. 2009 Dec;147(5):672-6.
    19751238
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
    19878638
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F, .NCCN clinical practice guidelines in oncology: multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):908-42.
    19878637
  • Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.British Journal of Haematology. 2009 Nov;147(4):531-4.
    19725827
  • Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC.Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.Blood. 2009 Oct 8;114(15):3276-84.
    19587378
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw..
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer Cell. 2009 Oct 6;16(4):309-23.
    19800576
  • Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM.Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.Clin Cancer Res. 2009 Oct 1;15(19):6035-41.
    19755386
  • Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR.BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.Cancer Res. 2009 Oct 1;69(19):7577-86.
    19738061
  • Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S.Prognostic significance of copy-number alterations in multiple myeloma.J Clin Oncol. 2009 Sep 20;27(27):4585-90.
    19687334
  • Laubach JP, Richardson PG, Anderson KC.Hematology: Thalidomide maintenance in multiple myeloma.Nat Rev Clin Oncol. 2009 Oct;6(10):565-6.
    19787000
  • Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR.Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.Blood. 2009 Sep 24;114(13):2699-708.
    19652203
  • Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N.High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.Clin Cancer Res. 2009 Sep 15;15(18):5829-39.
    19737962
  • Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV, .Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.Blood. 2009 Aug 27;114(9):1729-35.
    19561323
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Podar K, Hideshima T, Bianchi G, Mitsiades C, Raje N, Tai Y-T, Jaye DL, Kumar SK, Schlossman R, Richardson P, Munshi N, Anderson KC.Functional Interaction of plasmacytoid dendritic cells with multiple myeloma cells: a novel therapeutic target.Cancer Cell..
  • Hideshima T,Ikeda H,Chauhan D,Okawa Y,Raje N,Podar K,Mitsiades C,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.Blood. 2009 Jul 30;114(5):1046-52.
    19436050
  • Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.Multiple myeloma.Lancet. 2009 Jul 25;374(9686):324-39. Review.
    19541364
  • Richardson P,Jagannath S,Hussein M,Berenson J,Singhal S,Irwin D,Williams SF,Bensinger W,Badros AZ,Vescio R,Kenvin L,Yu Z,Olesnyckyj M,Zeldis J,Knight R,Anderson KC.Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.Blood. 2009 Jul 23;114(4):772-8.
    19471019
  • Azab AK,Azab F,Blotta S,Pitsillides CM,Thompson B,Runnels JM,Roccaro AM,Ngo HT,Melhem MR,Sacco A,Jia X,Anderson KC,Lin CP,Rollins BJ,Ghobrial IM.Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma.Blood. 2009 Jul 16;114(3):619-29.
    19443661
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.J Clin Oncol. 2009 Jul 20;27(21):3518-25.
    19528374
  • McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.Cancer Res. 2009 Jul 15;69(14):5835-42.
    19584292
  • Fulciniti M,Tassone P,Hideshima T,Vallet S,Nanjappa P,Ettenberg SA,Shen Z,Patel N,Tai YT,Chauhan D,Mitsiades C,Prabhala R,Raje N,Anderson KC,Stover DR,Munshi NC.Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.Blood. 2009 Jul 9;114(2):371-9.
    19417213
  • Potash J, Anderson KC.What's Your Line?.Clin Cancer Res. 2009 Jul 1;15(13):4251.
    19549765
  • Roccaro AM,Sacco A,Thompson B,Leleu X,Azab AK,Azab F,Runnels J,Jia X,Ngo HT,Melhem MR,Lin CP,Ribatti D,Rollins BJ,Witzig TE,Anderson KC,Ghobrial IM.microRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.Blood. 2009 Jun 25;113(26):6669-80.
    19401561
  • Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC.The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
    19509164
  • Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, Raab MS, Vallet S, Zhou Y, Cartron MA, Hideshima T, Tai YT, Chauhan D, Anderson KC, Podar K.Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.Cancer Res. 2009 Jun 15;69(12):5082-90.
    19509231
  • Laubach JP,Mitsiades CS,Roccaro AM,Ghobrial IM,Anderson KC,Richardson PG.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia.Leuk Lymphoma. 2009 May;50(5):694-702. Review.
    19452315
  • Anderson KC.Proteasome inhibitors in multiple myeloma.Semin Oncol. 2009 Apr;36(2 Suppl 1):S20-6.
    19393832
  • Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG.Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.Semin Hematol. 2009 Apr;46(2):166-75. Review.
    19389500
  • van Haaften G,Dalgliesh GL,Davies H,Chen L,Bignell G,Greenman C,Edkins S,Hardy C,O'Meara S,Teague J,Butler A,Hinton J,Latimer C,Andrews J,Barthorpe S,Beare D,Buck G,Campbell PJ,Cole J,Forbes S,Jia M,Jones D,Kok CY,Leroy C,Lin ML,McBride DJ,Maddison M,Maquire S,McLay K,Menzies A,Mironenko T,Mulderrig L,Mudie L,Pleasance E,Shepherd R,Smith R,Stebbings L,Stephens P,Tang G,Tarpey PS,Turner R,Turrell K,Varian J,West S,Widaa S,Wray P,Collins VP,Ichimura K,Law S,Wong J,Yuen ST,Leung SY,Tonon G,DePinho RA,Tai YT,Anderson KC,Kahnoski RJ,Massie A,Khoo SK,Teh BT,Stratton MR,Futreal PA.Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.Nat Genet. 2009 May;41(5):521-3.
    19330029
  • Hideshima T,Chauhan D,Kiziltepe T,Ikeda H,Okawa Y,Podar K,Raje N,Protopopov A,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.Blood. 2009 May 21;113(21):5228-36.
    19270264
  • Podar K,Tai YT,Hideshima T,Vallet S,Richardson PG,Anderson KC.Emerging therapies for multiple myeloma.Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. Review.
    19249983
  • Mitsiades CS,Rouleau C,Echart C,Menon K,Teicher B,Distaso M,Palumbo A,Boccadoro M,Anderson KC,Iacobelli M,Richardson PG.Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.Clin Cancer Res. 2009 Feb 15;15(4):1210-21.
    19228727
  • Tai YT,Soydan E,Song W,Fulciniti M,Kim K,Hong F,Li XF,Burger P,Rumizen MJ,Nahar S,Podar K,Hideshima T,Munshi NC,Tonon G,Carrasco RD,Afar DE,Anderson KC.CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.Blood. 2009 Apr 30;113(18):4309-18.
    19196658
  • Richardson PG,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Blade J,Boccadoro M,Cavenagh JD,Boral AL,Esseltine DL,Wen PY,Amato AA,Anderson KC,San Miguel J.Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.British Journal of Haematology. 2009 Mar;144(6):895-903.
    19170677
  • Bianchi G,Oliva L,Cascio P,Pengo N,Fontana F,Cerruti F,Orsi A,Pasqualetto E,Mezghrani A,Calbi V,Palladini G,Giuliani N,Anderson KC,Sitia R,Cenci S.The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.Blood. 2009 Mar 26;113(13):3040-9.
    19164601
  • Burger R,Le Gouill S,Tai YT,Shringarpure R,Tassone P,Neri P,Podar K,Catley L,Hideshima T,Chauhan D,Caulder E,Neilan CL,Vaddi K,Li J,Gramatzki M,Fridman JS,Anderson KC.Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.Mol Cancer Ther. 2009 Jan;8(1):26-35.
    19139110
  • Azab AK,Runnels JM,Pitsillides C,Moreau AS,Azab F,Leleu X,Jia X,Wright R,Ospina B,Carlson AL,Alt C,Burwick N,Roccaro AM,Ngo HT,Farag M,Melhem MR,Sacco A,Munshi NC,Hideshima T,Rollins BJ,Anderson KC,Kung AL,Lin CP,Ghobrial IM.CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.Blood. 2009 Apr 30;113(18):4341-51.
    19139079
  • Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA.Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):282-8.
    19124510
  • Anderson KC.Setting the standard for translational cancer research.Clin Cancer Res. 2009 Jan 1;15(1):1.
    19118025
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Chu L,Musto P,Baron AD,Nunnink JC,Kash JJ,Terjanian TO,Hyman PM,Nawfel EL,Sharon DJ,Munshi NC,Anderson KC.Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.Clin Cancer Res. 2009 Jan 1;15(1):355-60.
    19118065
  • Roccaro AM,Sacco A,Chen C,Runnels J,Leleu X,Azab F,Azab AK,Jia X,Ngo HT,Melhem MR,Burwick N,Varticovski L,Novina CD,Rollins BJ,Anderson KC,Ghobrial IM.microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia.Blood. 2009 Apr 30;113(18):4391-402.
    19074725
  • Chauhan D,Bianchi G,Anderson KC.Targeting the UPS as therapy in multiple myeloma.BMC Biochem. 2008;9 Suppl 1:S1. Review.
    19007431
  • Raab MS,Breitkreutz I,Tonon G,Zhang J,Hayden PJ,Nguyen T,Fruehauf JH,Lin BK,Chauhan D,Hideshima T,Munshi NC,Anderson KC,Podar K.Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.Blood. 2009 Feb 12;113(7):1513-21.
    19018094
  • Lee SJ,Richardson PG,Sonneveld P,Schuster MW,Irwin D,San Miguel JF,Crawford B,Massaro J,Dhawan R,Gupta S,Anderson KC.Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.British Journal of Haematology. 2008 Nov;143(4):511-9.
    18986387
  • Neri P,Tagliaferri P,Di Martino MT,Calimeri T,Amodio N,Bulotta A,Ventura M,Eramo PO,Viscomi C,Arbitrio M,Rossi M,Caraglia M,Munshi NC,Anderson KC,Tassone P.In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.British Journal of Haematology. 2008 Nov;143(4):520-31.
    18986388
  • Song W,van der Vliet HJ,Tai YT,Prabhala R,Wang R,Podar K,Catley L,Shammas MA,Anderson KC,Balk SP,Exley MA,Munshi NC.Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.Clin Cancer Res. 2008 Nov 1;14(21):6955-62.
    18980990
  • Cavo M,Attal M,Gertz MA,Giralt S,Ludwig H,Morgan GJ,Anderson KC.The current landscape of multiple myeloma treatment.Leuk Res. 2008 Dec;32 Suppl 1:S1-24.
    18954677
  • Okawa Y,Hideshima T,Steed P,Vallet S,Hall S,Huang K,Rice J,Barabasz A,Foley B,Ikeda H,Raje N,Kiziltepe T,Yasui H,Enatsu S,Anderson KC.SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.Blood. 2009 Jan 22;113(4):846-55.
    18948577
  • Nelson EA,Walker SR,Kepich A,Gashin LB,Hideshima T,Ikeda H,Chauhan D,Anderson KC,Frank DA.Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.Blood. 2008 Dec 15;112(13):5095-102.
    18824601
  • Bashey A,Perez WS,Zhang MJ,Anderson KC,Ballen K,Berenson JR,To LB,Fonseca R,Freytes CO,Gale RP,Gibson J,Giralt SA,Kyle RA,Lazarus HM,Maharaj D,McCarthy PL,Milone GA,Nimer S,Pavlovsky S,Reece DE,Schiller G,Vesole DH,Hari P.Comparison of twin and autologous transplants for multiple myeloma.Biol Blood Marrow Transplant. 2008 Oct;14(10):1118-24.
    18804041
  • Jagannath S,Barlogie B,Berenson JR,Siegel DS,Irwin D,Richardson PG,Niesvizky R,Alexanian R,Limentani SA,Alsina M,Esseltine DL,Anderson KC.Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.British Journal of Haematology. 2008 Nov;143(4):537-40.
    18783399
  • San Miguel JF,Schlag R,Khuageva NK,Dimopoulos MA,Shpilberg O,Kropff M,Spicka I,Petrucci MT,Palumbo A,Samoilova OS,Dmoszynska A,Abdulkadyrov KM,Schots R,Jiang B,Mateos MV,Anderson KC,Esseltine DL,Liu K,Cakana A,van de Velde H,Richardson PG.Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.N Engl J Med. 2008 Aug 28;359(9):906-17.
    18753647
  • Sonis ST,Watkins BA,Lyng GD,Lerman MA,Anderson KC.Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.Oral Oncol. 2009 Feb;45(2):164-72.
    18715819
  • Lonial S,Richardson PG,San Miguel J,Sonneveld P,Schuster MW,Blade J,Cavenagh J,Rajkumar SV,Jakubowiak AJ,Esseltine DL,Anderson KC,Harousseau JL.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.British Journal of Haematology. 2008 Oct;143(2):222-9.
    18713253
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Briccetti FM,Pasmantier M,Zimbler H,Cooper RB,Moore M,Hill J 2nd,Rauch A,Garbo L,Chu L,Chua C,Nantel SH,Lovett DR,Boedeker H,Sonneborn H,Howard J,Musto P,Ciccarelli BT,Hatjiharissi E,Anderson KC.Thalidomide and rituximab in Waldenstrom macroglobulinemia.Blood. 2008 Dec 1;112(12):4452-7.
    18713945
  • Chanan-Khan A,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Neuwirth R,Anderson KC,Richardson PG.Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.J Clin Oncol. 2008 Oct 10;26(29):4784-90.
    18711175
  • Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weler E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.Blood. 2008 Aug 15;112(4):1329-37.
    17906076
  • Tonon G,Anderson KC.Moving toward individualized cancer therapies.Clin Cancer Res. 2008 Aug 1;14(15):4682-4. Review.
    18676734
  • Niesvizky R,Richardson PG,Rajkumar SV,Coleman M,Rosinol L,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Boral AL,Esseltine DL,Anderson KC,Blade J.The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.British Journal of Haematology. 2008 Sep;143(1):46-53.
    18673366
  • Shammas MA,Qazi A,Batchu RB,Bertheau RC,Wong JY,Rao MY,Prasad M,Chanda D,Ponnazhagan S,Anderson KC,Steffes CP,Munshi NC,De Vivo I,Beer DG,Gryaznov S,Weaver DW,Goyal RK.Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.Clin Cancer Res. 2008 Aug 1;14(15):4971-80.
    18676772
  • Breitkreutz I,Anderson KC.Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85. Review.
    18624684
  • Mitsiades CS,Ocio EM,Pandiella A,Maiso P,Gajate C,Garayoa M,Vilanova D,Montero JC,Mitsiades N,McMullan CJ,Munshi NC,Hideshima T,Chauhan D,Aviles P,Otero G,Faircloth G,Mateos MV,Richardson PG,Mollinedo F,San-Miguel JF,Anderson KC.Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.Cancer Res. 2008 Jul 1;68(13):5216-25.
    18593922
  • Richardson PG,Mitsiades C,Schlossman R,Ghobrial I,Hideshima T,Munshi N,Anderson KC.Bortezomib in the front-line treatment of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. Review.
    18588451
  • Munshi NC,Mitsiades C,Richardson PG,Anderson KC.Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.Nat Clin Pract Oncol. 2008 Jul;5(7):374-5.
    18542118
  • San-Miguel J, Harousseau JL, Joshua D, Anderson KC.Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents.J Clin Oncol. 2008 Jun 1;26(16):2761-6. Review.
    18427148
  • Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC.p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.British Journal of Haematology. 2008 May;141(5):598-606.
    18397345
  • Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC.Fatty acid synthase is a novel therapeutic target in multiple myeloma.British Journal of Haematology. 2008 May;141(5):659-71.
    18410446
  • Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Leuk Lymphoma. 2008 Apr 23:1-8. Review.
    18452080
  • Chauhan D, Hideshima T, Anderson KC.Targeting proteasomes as therapy in multiple myeloma.Adv Exp Med Biol. 2008;615:251-60. Review.
    18437898
  • Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.Clin Cancer Res. 2008 Apr 15;14(8):2387-95.
    18413829
  • Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP.Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom's macroglobulinemia.Clin Cancer Res. 2008 Mar 15;14(6):1849-58.
    18347188
  • Richardson PG, Niesvizky R, Anderson KC, Blade J.Re: When you look matters: the effect of assessment schedule on progression-free survival.Journal of the National Cancer Institute. 2008 Mar 5;100(5):373.
    18314478
  • Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D.Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.Leuk Lymphoma. 2008 Mar;49(3):502-7.
    18297527
  • Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM.Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.Clin Cancer Res. 2008 Feb 1;14(3):865-74.
    18245550
  • Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL, Anderson KC.A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.Oncogene. 2008 Jan 31;27(6):721-31.
    17653083
  • Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT.Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.J Clin Invest. 2008 Feb;118(2):491-504.
    18219387
  • Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G.MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1285-90.
    18202175
  • McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH.Risks of cancer among a cohort of 23,935 men and women with osteoporosis.Int J Cancer. 2008 Apr 15;122(8):1879-84.
    18074348
  • Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG.From the bench to the bedside: emerging new treatments in multiple myeloma.Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816. Review.
    18070720
  • Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC.The malignant clone and the bone-marrow environment.Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612. Review.
    18070708
  • Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC.Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.Blood. 2008 Feb 1;111(3):1654-64.
    18006697
  • Hideshima T, Anderson KC.Preclinical studies of novel targeted therapies.Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. Review.
    17996589
  • Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA.Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.Clin Cancer Res. 2007 Oct 15;13(20):6162-7.
    17947482
  • Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N.Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.Clin Cancer Res. 2007 Oct 1;13(19):5903-9.
    17908986
  • Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.Novel therapies in myeloma.Curr Opin Hematol. 2007 Nov;14(6):609-15. Review.
    17898564
  • Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP.Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIA-158 V/V and V/F polymorphism.Blood. 2007 Oct 1;110(7):2561-4.
    17475906
  • Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC.Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.British Journal of Haematology. 2007 Oct;139(1):55-63.
    17854307
  • Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.British Journal of Haematology. 2007 Sep;138(6):783-91.
    17760810
  • Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM.The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.Blood. 2007 Dec 15;110(13):4417-26.
    17761832
  • Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP.Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.Exp Hematol. 2007 Sep;35(9):1366-75.
    17761288
  • Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC.MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.Blood. 2007 Nov 15;110(10):3744-52.
    17715391
  • Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC.Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis.Blood. 2007 Sep 1;110(5):1656-63.
    17510321
  • Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.Nat Rev Cancer. 2007 Aug;7(8):585-98. Review.
    17646864
  • Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC.JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.Blood. 2007 Jul 15;110(2):709-18.
    17384201
  • Munshi NC, Mitsiades CS, Richardson PG, Anderson KC.Does maintenance therapy with thalidomide benefit patients with multiple myeloma?.Nat Clin Pract Oncol. 2007 Jul;4(7):394-5.
    17534287
  • Catley L, Hideshima T, Chauhan D, Neri P, Tassone P, Bronson R, Song W, Tai YT, Munshi NC, Anderson KC.Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.Exp Hematol. 2007 Jul;35(7):1038-46.
    17588472
  • Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC.5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.Mol Cancer Ther. 2007 Jun;6(6):1718-27.
    17575103
  • Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, Li C, Catley L, Prabhala R, Anderson KC, Munshi NC.Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.J Immunol. 2007 Jun 15;178(12):7730-7.
    17548610
  • Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.British Journal of Haematology. 2007 Jun;137(5):429-35.
    17451408
  • Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR.Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.Proc Natl Acad Sci U S A. 2007 May 1;104(18):7516-21.
    17452641
  • Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM.Proteomic analysis of waldenstrom macroglobulinemia.Cancer Res. 2007 Apr 15;67(8):3777-84.
    17440091
  • Podar K, Richardson PG, Chauhan D, Anderson KC.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Expert Rev Anticancer Ther. 2007 Apr;7(4):551-66. Review.
    17428175
  • Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, Zheng M, Mani M, Henderson J, Pinkus GS, Munshi N, Horner J, Ivanova EV, Protopopov A, Anderson KC, Tonon G, DePinho RA.The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.Cancer Cell. 2007 Apr;11(4):349-60.
    17418411
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery .Corrigendum: High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Apr;39(4):567.
    17392811
  • Richardson PG, Hideshima T, Mitsiades C, Anderson KC.The emerging role of novel therapies for the treatment of relapsed myeloma.J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.
    17335684
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F,.Multiple myeloma. Clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2007 Feb;5(2):118-47.
    17335683
  • Podar K, Raab MS, Tonon G, Sattler M, Baril D, Zhang J, Tai YT, Yasui H, Raje N, Depinho RA, Hideshima T, Chauhan D, Anderson KC.Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.Cancer Res. 2007 Feb 15;67(4):1680-1688.
    17308109
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA.High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Mar;39(3):347-351.
    17293865
  • Moreau AS, Jia X, Ngo HT, Leleu X, O'sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM.Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.Blood. 2007 Jun 1;109(11):4964-72.
    17284528
  • Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC.Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.Leukemia. 2007 Mar;21(3):535-40.
    17268521
  • Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP.High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.Biol Blood Marrow Transplant. 2007 Feb;13(2):183-96. Review.
    17241924
  • Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.Blood. 2007 Apr 15;109(8):3177-88.
    17185464
  • Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.Br J Haematol. 2007 Feb;136(3):414-23.
    17173546
  • Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC.The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83.
    17164332
  • Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.Clin Cancer Res. 2006 Nov 15;12(22):6826-35.
    17121904
  • Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Ct D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM.Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.Blood. 2007 Apr 1;109(7):2708-17.
    17119115
  • Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC.Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.Leukemia. 2007 Jan;21(1):151-7.
    17096017
  • Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC.Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.Blood. 2006 Nov 15;108(10):3441-9.
    16728695
  • Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC.A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood. 2006 Nov 15;108(10):3458-64.
    16840727
  • Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK, Munshi N, Hideshima T, Chauhan D, Anderson KC.Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).Blood. 2007 Feb 15;109(4):1669-77.
    17023575
  • Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC.Specific killing of multiple myeloma cells by (-)- epigallocatechin-3-gallate extracted from green tea: biological activity and therapeutic implications.Blood. 2006 Oct 15;108(8):2804-10.
    16809610
  • Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Hankinson SE, Larsson SC, Leitzmann M, Marshall JR, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten LJ, Willett WC, Wolk A, Zhang SM, Smith-Warner SA.Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies.Int J Cancer. 2006 Nov 1;119(9):2148-54.
    16823847
  • Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC.The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions.Eur J Cancer. 2006 Jul;42(11):1564-73. Review.
    16765041
  • Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP.Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.Ann Oncol. 2006 Aug;17(8):1275-82.
    16788002
  • Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.Br J Haematol. 2006 Jul;134(2):145-56.
    16846475
  • Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC,.Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.Haematologica. 2006 Jul;91(7):929-34.
    16818280
  • Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.Cancer Res. 2006 Jul 1;66(13):6675-82.
    16818641
  • Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Laurence CP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC.In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.Br J Haematol. 2006 Jul;134(1):37-44.
    16803565
  • Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP.CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.Clin Lymphoma Myeloma. 2006 May;6(6):478-83.
    16796779
  • Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.J Clin Oncol. 2006 Jul 1;24(19):3113-20.
    16754936
  • Mitsiades CS, Richardson PG, Anderson KC.The theraputic use of vitamin K compounds in multiple myeloma.Haematologica. 2006 May;91(5):578b.
    16670056
  • Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.Leukemia. 2006 Jun;20(6):1017-27.
    16617327
  • Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA.High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.Cancer Cell. 2006 Apr;9(4):313-25.
    16616336
  • Richardson PG, Schlossman R, Hideshima T, Anderson KC.New treatments for multiple myeloma.Oncology (Huntingt). 2005 Dec;19(14):1781-92; discussion 1792,. Review.
    16506632
  • Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, Buring JE, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Jacobs DR Jr, Koushik A, Lacey JV Jr, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Schouten LJ, Shore R, Smit E, Wolk A, Zhang SM, Smith-Warner SA.Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies.Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):364-72.
    16492930
  • Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Harnack L, Hankinson SE, Larsson SC, Leitzmann M, McCullough ML, Marshall J, Miller AB, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Wolk A, Zhang SM, Smith-Warner SA.Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies.Br J Cancer. 2006 Mar 13;94(5):757-62.
    16495916
  • Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Beeson WL, Buring JE, Colditz GA, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten LJ, Smit E, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Smith-Warner SA.A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer.Cancer Causes Control. 2006 Apr;17(3):273-85.
    16489535
  • Podar K, Anderson KC.Caveolin-1 as a potential new therapeutic target in multiple myeloma.Cancer Lett. 2006 Feb 20;233(1):10-5. Review.
    16473666
  • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.Cancer. 2006 Mar 15;106(6):1316-9.
    16470606
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.Anti-myeloma activity of heat shock protein-90 inhibition.Blood. 2006 Feb 1;107(3):1092-100.
    16234364
  • Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.J Clin Oncol. 2006 Feb 20;24(6):929-36.
    16432076
  • Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.Blood. 2006 May 15;107(10):4053-62.
    16418332
  • Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Bortezomib: proteasome inhibition as an effective anticancer therapy.Annu Rev Med. 2006;57:33-47. Review.
    16409135
  • Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.Cancer Res. 2006 Jan 1;66(1):184-91.
    16397231
  • Hideshima T, Bradner JE, Chauhan D, Anderson KC.Intracellular protein degradation and its therapeutic implications.Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8530-3.
    16361533
  • Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.Cancer Cell. 2005 Nov;8(5):407-19.
    16286248
  • Kumar S, Anderson KC.Drug insight: thalidomide as a treatment for multiple myeloma.Nat Clin Pract Oncol. 2005 May;2(5):262-70.
    16264962
  • Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Arslan AA, Beeson WL, van den Brandt PA, Buring JE, Cerhan JR, Colditz GA, Fraser GE, Freudenheim JL, Genkinger JM, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Patel A, Rohan TE, Schatzkin A, Smit E, Willett WC, Wolk A, Zhang SM, Smith-Warner SA.Fruits and vegetables and ovarian cancer risk in a pooled analysis of 12 cohort studies.Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2160-7.
    16172226
  • Anderson KC, Pazdur R, Farrell AT.Development of effective new treatments for multiple myeloma.J Clin Oncol. 2005 Oct 1;23(28):7207-11.
    16145064
  • Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG.FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.Oncogene. 2005 Dec 15;24(56):8259-67.
    16091734
  • Richardson PG, Mitsiades CS, Hideshima T, Anderson KC.Novel biological therapies for the treatment of multiple myeloma.Best Pract Res Clin Haematol. 2005;18(4):619-34.
    16026741
  • Catley L, Tai YT, Chauhan D, Anderson KC.Perspectives for combination therapy to overcome drug-resistant multiple myeloma.Drug Resist Updat. 2005 Aug;8(4):205-18.
    16019253
  • Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.Proteasome inhibition as a therapeutic strategy for hematologic malignancies.Expert Rev Anticancer Ther. 2005 Jun;5(3):465-76.
    16001954
  • Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC.Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.Cancer Res. 2005 Jul 1;65(13):5898-906.
    15994968
  • Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC.A clinically relevant SCID-hu in vivo model of human multiple myeloma.Blood. 2005 Jul 15;106(2):713-6.
    15817674
  • Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med. 2005 Jun 16;352(24):2487-98.
    15958804
  • Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC.Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72.
    15937109
  • Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D.Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.Br J Haematol. 2005 Jun;129(5):687-700.
    15916692
  • Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC.Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.Blood. 2005 Sep 1;106(5):1794-800.
    15870175
  • Anderson KC.Clinical update: novel targets in multiple myeloma.Semin Oncol. 2004 Dec;31(6 Suppl 16):27-32; discussion 33.
    15799242
  • Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D, Richardson P, Schlossman R, Choi PS, Grogins J, O'Connor PG, Cohen K, Attar EC, Freshman J, Rich R, Mangano JA, Gribben JG, Anderson KC, Scadden DT.Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.Blood. 2005 Mar 1;105(5):2235-8.
    15292069
  • Bellucci R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, Wu B, Canning C, Schlossman R, Munshi NC, Anderson KC, Ritz J.Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.Blood. 2005 May 15;105(10):3945-50.
    15692072
  • Rajkumar SV, Richardson PG, Hideshima T, Anderson KC.Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Oncol. 2005 Jan 20;23(3):630-9.
    15659509
  • Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA.Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrm's macroglobulinemia.J Clin Oncol. 2005 Jan 20;23(3):474-81.
    15659493
  • Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Proteasome inhibition in the treatment of cancer.Cell Cycle. 2005 Feb;4(2):290-6.
    15655370
  • Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC.Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br J Haematol. 2005 Jan;128(2):192-203.
    15638853
  • Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR,.Extended rituximab therapy in Waldenstrm's macroglobulinemia.Ann Oncol. 2005 Jan;16(1):132-8.
    15598950
  • Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC.VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis.Blood. 2004 Nov 1;104(9):2886-92.
    15217829
  • Podar K, Anderson KC.The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.Blood. 2005 Feb 15;105(4):1383-95.
    15471951
  • Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC.Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.Blood. 2005 Jan 1;105(1):350-7.
    15367426
  • Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC.Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.Cancer Res. 2004 Apr 15;64(8):2846-52.
    15087402
  • Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol. 2004 May;125(3):343-52.
    15086415
  • Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Blood. 2004 Apr 15;103(8):3158-66.
    15070698
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garca-Echeverra C, Pearson MA, Hofmann F, Anderson KC, Kung AL.Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.Cancer Cell. 2004 Mar;5(3):221-30.
    15050914
  • Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC.2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.Apoptosis. 2004 Mar;9(2):149-55.
    15004512
  • Hideshima T, Richardson PG, Anderson KC.Targeting proteasome inhibition in hematologic malignancies.Rev Clin Exp Hematol. 2003 Jun;7(2):191-204.
    14763162
  • Shammas MA, Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC.Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.Clin Cancer Res. 2004 Jan 15;10(2):770-6.
    14760100
  • Anderson KC.Stem cell transplantation for myeloma.Curr Hematol Rep. 2004 Jan;3(1):65-6.
    14695853
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5.
    14695887
  • Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC.Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.Cancer Res. 2003 Dec 1;63(23):8428-36.
    14679006
  • Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.Bone Marrow Transplant. 2003 Dec;32(12):1145-51.
    14647268
  • Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC.GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.Blood. 2004 May 1;103(9):3474-9.
    14644994
  • Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC.Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.Oncogene. 2003 Nov 20;22(52):8386-93.
    14627979
  • Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC.Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.Br J Haematol. 2003 Dec;123(5):869-78.
    14632778
  • Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC.Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.Cancer Res. 2003 Oct 15;63(20):6689-96.
    14583463
  • Richardson PG, Hideshima T, Anderson KC.Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.Cancer Control. 2003 Sep-Oct;10(5):361-9.
    14581890
  • Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP, Dranoff G, Anderson KC, Munshi NC, Ritz J.Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.Blood. 2004 Jan 15;103(2):656-63.
    14563636
  • Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC.Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.Cancer Res. 2003 Oct 1;63(19):6174-7.
    14559800
  • Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.Cancer Res. 2003 Oct 1;63(19):6187-94.
    14559802
  • Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC.Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.Mol Cancer Ther. 2003 Sep;2(9):825-33.
    14555701
  • Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC.Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.Cancer Res. 2003 Sep 15;63(18):5850-8.
    14522909
  • LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC.Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.Blood. 2004 Mar 1;103(5):1787-90.
    14512311
  • Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, Anderson KC.Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.Oncogene. 2003 Sep 18;22(40):6296-300.
    13679868
  • Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC.Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.Blood. 2003 Dec 15;102(13):4504-11.
    12947006
  • Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH.Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51.
    12902539
  • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med. 2003 Jun 26;348(26):2609-17.
    12826635
  • Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.Blood. 2003 Oct 1;102(7):2615-22.
    12816865
  • Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL.Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.Br J Haematol. 2003 Jun;121(6):842-8.
    12786794
  • Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC.Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.Br J Haematol. 2003 May;121(4):592-6.
    12752100
  • Orsini E, Bellucci R, Alyea EP, Schlossman R, Canning C, McLaughlin S, Ghia P, Anderson KC, Ritz J.Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.Cancer Res. 2003 May 15;63(10):2561-8.
    12750280
  • Akiyama M, Hideshima T, Munshi NC, Anderson KC.Telomerase inhibitors as anticancer therapy.Curr Med Chem Anti-Canc Agents. 2002 Sep;2(5):567-75.
    12678724
  • Anderson KC.Moving disease biology from the lab to the clinic.Cancer. 2003 Feb 1;97(3 Suppl):796-801.
    12548578
  • Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood. 2003 May 15;101(10):4055-62.
    12531799
  • Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, Anderson KC.Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.Leukemia. 2003 Jan;17(1):41-4.
    12529658
  • Anderson KC.Moving disease biology from the laboratory to the clinic.Semin Oncol. 2002 Dec;29(6 Suppl 17):17-20.
    12520480
  • Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.Cancer Res. 2003 Jan 1;63(1):18-21.
    12517770
  • Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC.Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.Mol Cancer Ther. 2002 Aug;1(10):851-60.
    12492118
  • Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC.Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.J Biol Chem. 2003 Feb 21;278(8):5794-801.
    12482878
  • Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC.Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.Blood. 2003 May 1;101(9):3606-14.
    12480690
  • Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC.The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.Mol Cancer Ther. 2002 May;1(7):539-44.
    12479272
  • Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.Biol Blood Marrow Transplant. 2002;8(11):625-32.
    12463482
  • Hideshima T, Anderson KC.Molecular mechanisms of novel therapeutic approaches for multiple myeloma.Nat Rev Cancer. 2002 Dec;2(12):927-37.
    12459731
  • Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC.CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.Blood. 2003 Apr 1;101(7):2762-9.
    12433678
  • Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood. 2003 Mar 15;101(6):2377-80.
    12424198
  • Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC.Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.Blood. 2003 Jan 15;101(2):703-5.
    12393542
  • Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.Blood. 2003 Feb 15;101(4):1530-4.
    12393500
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.Molecular sequelae of proteasome inhibition in human multiple myeloma cells.Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9.
    12391322
  • Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood. 2002 Nov 1;100(9):3063-7.
    12384400
  • Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.Cancer Res. 2002 Sep 1;62(17):5019-26.
    12208756
  • LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC.Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.Cancer Res. 2002 Sep 1;62(17):4996-5000.
    12208752
  • Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC.2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Blood. 2002 Sep 15;100(6):2187-94.
    12200384
  • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene. 2002 Aug 22;21(37):5673-83.
    12173037
  • Gupta D, Podar K, Tai YT, Lin B, Hideshima T, Akiyama M, LeBlanc R, Catley L, Mitsiades N, Mitsiades C, Chauhan D, Munshi NC, Anderson KC.beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.Exp Hematol. 2002 Jul;30(7):711-20.
    12135668
  • Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Cytokines modulate telomerase activity in a human multiple myeloma cell line.Cancer Res. 2002 Jul 1;62(13):3876-82.
    12097303
  • Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Weaver WD, Gibler WB, Stebbins AL, Califf RM, Topol EJ.Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.Am Heart J. 2002 Jul;144(1):81-8.
    12094192
  • Brander C, Raje N, O'Connor PG, Davies F, Davis J, Chauhan D, Hideshima T, Martin J, Osmond D, Kedes DH, Walker BD, Scadden DT, Anderson KC.Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.Blood. 2002 Jul 15;100(2):698-700.
    12091368
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood. 2002 Jun 15;99(12):4525-30.
    12036884
  • Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, Canning C, Schlossman R, Soiffer RJ, Anderson KC, Ritz J.Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.Blood. 2002 Jun 15;99(12):4610-7.
    12036895
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.Blood. 2002 Jun 1;99(11):4079-86.
    12010810
  • Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R, Fisher D, Gribben J, Ritz J, Soiffer R.Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.Biol Blood Marrow Transplant. 2002;8(3):139-44.
    11939603
  • Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D.Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.Blood. 2002 Apr 1;99(7):2512-7.
    11895787
  • Tai YT, Podar K, Kraeft SK, Wang F, Young G, Lin B, Gupta D, Chen LB, Anderson KC.Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.Exp Hematol. 2002 Mar;30(3):212-20.
    11882358
  • Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.Blood. 2002 Mar 15;99(6):2162-71.
    11877293
  • Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC.NF-kappa B as a therapeutic target in multiple myeloma.J Biol Chem. 2002 May 10;277(19):16639-47.
    11872748
  • Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, Mizoguchi H, Eto Y, Anderson KC, Yamada H.Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors.Cancer Lett. 2002 Apr 25;178(2):187-97.
    11867204
  • Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC.Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.Oncogene. 2002 Feb 21;21(9):1346-58.
    11857078
  • Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.Expert Opin Investig Drugs. 2001 Aug;10(8):1521-30.
    11772267
  • Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC.Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.Expert Opin Investig Drugs. 2001 Jun;10(6):1075-84.
    11772236
  • Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC.Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.J Biol Chem. 2002 Mar 8;277(10):7875-81.
    11751905
  • Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC.Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.Leukemia. 2001 Dec;15(12):1950-61.
    11753617
  • D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS.Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.Semin Oncol. 2001 Dec;28(6):597-601.
    11740816
  • Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.Novel therapies targeting the myeloma cell and its bone marrow microenvironment.Semin Oncol. 2001 Dec;28(6):607-12.
    11740818
  • Hideshima T, Nakamura N, Chauhan D, Anderson KC.Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.Oncogene. 2001 Sep 20;20(42):5991-6000.
    11593406
  • Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.Blood. 2001 Aug 1;98(3):795-804.
    11468181
  • Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.J Immunother. 2001 May-Jun;24(3):272-9.
    11394506
  • Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM.A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.Br J Haematol. 2001 May;113(2):455-60.
    11380416
  • Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res. 2001 Apr 1;61(7):3071-6.
    11306489
  • Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.J Clin Oncol. 2001 Feb 15;19(4):1152-9.
    11181681
  • Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC.Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.J Immunol. 2000 Dec 1;165(11):6347-55.
    11086072
  • Treon SP, Maimonis P, Bua D, Young G, Raje N, Mollick J, Chauhan D, Tai YT, Hideshima T, Shima Y, Hilgers J, von Mensdorff-Pouilly S, Belch AR, Pilarski LM, Anderson KC.Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.Blood. 2000 Nov 1;96(9):3147-53.
    11049996
  • Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000 Nov 1;96(9):2943-50.
    11049970
  • Orsini E, Alyea EP, Chillemi A, Schlossman R, McLaughlin S, Canning C, Soiffer RJ, Anderson KC, Ritz J.Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.Biol Blood Marrow Transplant. 2000;6(4):375-86.
    10917573
  • Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC.SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.J Biol Chem. 2000 Sep 8;275(36):27845-50.
    10880513
  • Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, Anderson KC, Gribben JG.Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.Biol Blood Marrow Transplant. 2000;6(3):241-53.
    10871149
  • Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC.Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.Clin Cancer Res. 2000 Mar;6(3):1180-9.
    10741750
  • Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, Neuberg D, Anderson KC, Ritz J.Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.Bone Marrow Transplant. 2000 Mar;25(6):623-32.
    10734296
  • Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S, Anderson KC.RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.Oncogene. 1999 Nov 18;18(48):6733-40.
    10597281
  • Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC.Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.Semin Oncol. 1999 Oct;26(5 Suppl 14):97-106.
    10561024
  • Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG.Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999 Nov 15;94(10):3325-33.
    10552941
  • Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS.Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.Biol Blood Marrow Transplant. 1999;5(4):262-8.
    10465106
  • Chauhan D, Hideshima T, Treon S, Teoh G, Raje N, Yoshihimito S, Tai YT, Li W, Fan J, DeCaprio J, Anderson KC.Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells.Cancer Res. 1999 Mar 15;59(6):1192-5.
    10096546
  • Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus GS, Pinkus JL, Teoh G, Hideshima T, Treon SP, Fingeroth JD, Anderson KC.Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.Blood. 1999 Mar 1;93(5):1482-6.
    10029574
  • Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC.Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.Blood. 1999 Mar 1;93(5):1487-95.
    10029575
  • Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC.Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.Blood. 1999 Feb 15;93(4):1287-98.
    9949172
  • Teoh G, Chen L, Urashima M, Tai YT, Celi LA, Chen D, Chauhan D, Ogata A, Finberg RW, Webb IJ, Kufe DW, Anderson KC.Adenovirus vector-based purging of multiple myeloma cells.Blood. 1998 Dec 15;92(12):4591-601.
    9845525
  • Webb IJ, Beach M, Daley JF, Schott DM, Anderson KC.Sequential CD34+ and CD4+ cell selection from leukapheresis components.J Hematother. 1998 Apr;7(2):169-74.
    9597574
  • Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, Schlossman RL, Anderson KC.MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells.Blood. 1997 Sep 1;90(5):1982-92.
    9292533
  • Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC.The development of a model for the homing of multiple myeloma cells to human bone marrow.Blood. 1997 Jul 15;90(2):754-65.
    9226176
  • Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC.Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.Blood. 1997 Jan 1;89(1):227-34.
    8978296
  • Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC.Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.Blood. 1996 Feb 1;87(3):1104-12.
    8562936
  • Chauhan D, Kharbanda SM, Ogata A, Urashima M, Frank D, Malik N, Kufe DW, Anderson KC.Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.J Exp Med. 1995 Dec 1;182(6):1801-6.
    7500025
  • Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC.CD40 ligand triggered interleukin-6 secretion in multiple myeloma.Blood. 1995 Apr 1;85(7):1903-12.
    7535594
  • Anderson KC, Andersen J, Soiffer R, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Blake K, Murray C, Freeman A.Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma.Blood. 1993 Oct 15;82(8):2568-76.
    8400304